Y90 Procedure: How Radioembolization Treats Liver Cancer

The Y90 procedure, formally called yttrium-90 radioembolization, is a minimally invasive treatment that delivers millions of tiny radioactive beads directly into the blood vessels feeding liver tumors. An interventional radiologist threads a catheter from the groin into the hepatic artery and releases microspheres loaded with yttrium-90, a radioactive isotope that emits high-energy radiation over a short range. The beads lodge in and around the tumor’s blood supply, irradiating cancer cells from the inside while largely sparing healthy liver tissue. First investigated in the 1960s and refined with modern microsphere technology in the early 1990s, Y90 radioembolization has become a standard option for patients with primary liver cancer and certain cancers that have spread to the liver.

Why the Liver Is Uniquely Suited to This Approach

The procedure exploits a quirk of liver anatomy. Healthy liver cells get most of their blood from the portal vein, with only about 10 to 35 percent coming from the hepatic artery. Tumors in the liver flip that ratio: malignant cells draw the bulk of their blood supply from branches of the hepatic artery.¹ When microspheres are injected into the hepatic artery, they preferentially flow toward the tumor-rich areas rather than the surrounding healthy tissue. This built-in selectivity is what makes Y90 effective and relatively tolerable: the radiation dose concentrates where the cancer is, while the rest of the liver sees comparatively little exposure.

Glass Versus Resin Microspheres

Two types of Y90 microspheres are commercially available, and your treatment center’s choice between them affects how the procedure is planned and delivered. Glass microspheres carry roughly 50 times more radioactivity per bead at the time of manufacture and are denser, which means fewer beads are needed per treatment and they cause minimal blockage of blood vessels. Resin microspheres are less radioactive per bead, so many more are required to deliver the same radiation dose; the larger bead load also produces a mild embolization effect, partially blocking blood flow to the tumor on top of the radiation damage.² Both types are widely used, and research comparing them head-to-head is still evolving. In practice, the choice often depends on the institution’s experience, the patient’s tumor burden, and the dosimetry approach the team prefers.

What Happens Before the Procedure

Y90 is not a walk-in treatment. It requires careful staging work, typically including a preparatory angiogram and a test run with a stand-in tracer, all done days to weeks before the actual treatment.

During the mapping angiogram, the interventional radiologist threads a catheter into the hepatic artery to map the blood vessels feeding the liver and any tumors. This step identifies variant anatomy, since the liver’s arterial plumbing varies from person to person. In some cases, extra arterial branches that might carry microspheres to unintended destinations are deliberately blocked off (embolized) to simplify the delivery path and ensure whole-liver coverage when it is needed.³

At the same session, the team typically injects a tracer called technetium-99m macroaggregated albumin (Tc-99m MAA) through the catheter. This tracer mimics where the microspheres will go once they are released. Imaging with SPECT/CT afterward lets the team measure the lung shunt fraction, which is the percentage of tracer that escapes through the liver’s blood vessels into the lungs.⁴ If too much tracer reaches the lungs, it means too many microspheres would also end up there during actual treatment, risking radiation pneumonitis. A high lung shunt fraction may require a dose reduction or, in extreme cases, can disqualify someone from the procedure entirely.

The tracer run also reveals whether any microspheres might drift into the stomach, intestines, or other organs. Catching these detours before the real treatment is the whole point of the rehearsal.

Dosimetry and Dose Planning

Deciding how much activity to inject is one of the most important and technically complex parts of Y90 treatment. Three dosimetry models are used in clinical practice: the body surface area model, the medical internal radiation dose (MIRD) model, and the partition model.⁵ Each estimates the dose differently, balancing simplicity against accuracy.

The body surface area method is the simplest: it uses a patient’s height, weight, and the percentage of liver involved by tumor to calculate the dose. It is quick but relatively blunt. The MIRD model incorporates the mass of the target liver lobe for a more tailored estimate. The partition model goes further, breaking the dose calculation into separate compartments for tumor tissue, normal liver, and lung shunt, aiming to maximize the tumor dose while keeping healthy tissue below safe thresholds. Evidence suggests that using partition-model dosimetry may improve treatment response. In one retrospective analysis of colorectal cancer liver metastases treated with resin microspheres, a far greater proportion of patients who responded to treatment had their doses calculated using partition modeling compared to those who did not respond.⁶ The trend in the field is moving toward more personalized dosimetry, though not all centers have adopted the more complex models.

Which Cancers It Treats

Y90 is most commonly used for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It is also used for cancers that have metastasized to the liver, particularly colorectal cancer and neuroendocrine tumors. In each setting, the goals and expected outcomes differ.

Hepatocellular Carcinoma

For HCC, Y90 can serve several roles. In patients with early- to intermediate-stage disease who cannot undergo surgery, it can be a definitive local treatment. In more advanced cases, particularly those with tumor invading the portal vein (a significant complication called portal vein thrombosis), Y90 is increasingly used to shrink tumors enough that a patient becomes eligible for liver transplantation. One study found that radioembolization successfully downstaged roughly one in four patients with portal vein tumor thrombosis to transplant eligibility, and those who then received a transplant had substantially better long-term cancer outcomes.⁷ Y90 can also serve as a bridge for patients already on the transplant waiting list, keeping tumors controlled so the patient remains eligible while waiting for a donor organ. In some cases, it achieves complete pathological necrosis, meaning no living cancer cells remain in the removed liver after transplant.⁸

Colorectal Cancer Liver Metastases

The liver is the most common site for colorectal cancer to spread, and when standard chemotherapy stops working, options narrow. Y90 has been studied extensively in this salvage setting. A systematic review concluded that Y90 is safe and effective for patients with colorectal cancer liver metastases who have failed chemotherapy.⁹ In one large series following 214 patients over 12 years, median survival from the time of Y90 treatment was about 10.6 months, while median survival from the original cancer diagnosis was about 43 months.¹⁰ Those numbers reflect a heavily pretreated population, and outcomes can be better in patients treated earlier in their disease course.

Neuroendocrine Tumor Liver Metastases

Neuroendocrine tumors that spread to the liver can be difficult to manage, especially when surgery is not feasible. Y90 has shown promise here as well. In one study, about 86 percent of patients achieved some degree of disease control (complete response, partial response, or stable disease), with low rates of serious side effects.¹¹ A larger international multicenter study reported a disease control rate of about 84 percent at three months and median overall survival of roughly 39 months.¹² Research into dosimetry for neuroendocrine metastases has suggested that achieving a minimum planned tumor dose of 150 Gy is important for a good response, underscoring how dose planning matters in this population.¹³

How Y90 Compares to Chemoembolization

The most frequent comparison is between Y90 (also called transarterial radioembolization, or TARE) and transarterial chemoembolization (TACE), which delivers chemotherapy drugs directly into the tumor’s blood supply while simultaneously blocking those vessels. Both are catheter-based treatments for liver tumors, but they work by different mechanisms.

A meta-analysis comparing the two for HCC found that one-year survival was virtually identical between Y90 and TACE. However, as time passed, the advantage tilted toward Y90: two-year and three-year survival rates were significantly better in the radioembolization group. Y90 also delayed tumor progression significantly longer.¹⁴ A separate meta-analysis confirmed these patterns, finding that Y90 was associated with better overall survival and longer time to tumor progression, along with shorter hospital stays and less abdominal pain.¹⁵

A phase II randomized trial (the TRACE trial) provided some of the clearest comparative data. Patients treated with Y90 had a median time to tumor progression of about 17 months compared to roughly 9.5 months with drug-eluting bead TACE, and median overall survival was about 30 months versus about 16 months. Rates of serious side effects were similar between the two arms.¹⁶ These findings together suggest that Y90 may offer a meaningful advantage in keeping tumors from growing back, even if the two treatments look similar in the short term.

Radiation Segmentectomy and Radiation Lobectomy

Beyond treating the whole liver or a lobe, Y90 can be focused down to just one or two liver segments in a technique called radiation segmentectomy. The idea is to deliver a very high, ablative dose of radiation to a small portion of the liver, effectively destroying the tumor and the surrounding segment. Because only a small volume of liver is irradiated, the procedure is well tolerated and can be done as an outpatient treatment. It has gained acceptance as a potentially curative option for selected patients with early-stage HCC.¹⁷

Radiation lobectomy takes the opposite approach in terms of scale: it delivers a high dose to an entire lobe of the liver, ablating it. This has a dual purpose in some patients. It treats tumors in the targeted lobe while simultaneously causing the untreated lobe to grow larger (a process called contralateral hypertrophy). That growth can make patients who were previously inoperable eligible for surgical resection, because the remaining liver is now large enough to sustain the patient after surgery. The concept is similar to portal vein embolization, a standard surgical preparation technique, but radiation lobectomy also treats the cancer in the process.

Complications and Side Effects

Y90 is generally well tolerated, especially compared to systemic chemotherapy or surgical resection. The most common side effect is post-radioembolization syndrome, a constellation of fatigue, nausea, mild abdominal pain, and occasionally low-grade fever that develops in the days and weeks after treatment. For most patients this resolves on its own and is managed with supportive care.

More serious complications fall into a few categories. Radioembolization-induced liver disease (REILD) is a form of liver injury caused by radiation damage to healthy liver tissue, particularly dangerous in patients whose liver function is already compromised. Biliary injury can occur when radiation affects the bile ducts. Off-target delivery of microspheres, despite the careful pre-procedure planning, can lead to radiation gastritis, gastrointestinal ulcers, cholecystitis (gallbladder inflammation), or radiation pneumonitis if beads reach the lungs.¹⁸ The extensive pre-procedure work described earlier, including angiographic mapping, coil embolization of problematic vessels, and lung shunt fraction measurement, exists precisely to minimize these risks.¹⁹

What Happens After Treatment

Once the microspheres are in place, the yttrium-90 does its work over the following days and weeks. The isotope has a half-life of about 64 hours, meaning most of the radiation is delivered within the first two weeks. The beads themselves stay permanently in the liver but become inert once the isotope decays.

Immediately after the procedure, a PET/CT or SPECT/CT scan is often performed to verify where the microspheres actually landed. Y90 PET/CT has been shown to be superior to older bremsstrahlung SPECT/CT imaging for assessing both target and non-target activity.²⁰ This verification step helps the treatment team confirm that the dose was delivered as planned and that no significant off-target deposition occurred.

Tumor response is typically assessed with multiphase CT or MRI at intervals after treatment, often starting around one month and again at three to six months. Researchers have also explored early PET/CT scans as a way to predict longer-term response sooner, though this remains an area of active investigation.²¹ Modified RECIST criteria, which assess how much of the tumor’s blood supply has been destroyed rather than just measuring tumor size, are the preferred method for evaluating response to Y90.²² A tumor may not shrink immediately but can show loss of arterial enhancement on imaging, signaling that the cancer cells are dying even before the mass gets smaller.

Radiation Safety After Discharge

A common concern for patients and their families is whether being around the treated person poses a radiation risk. Because yttrium-90 emits beta radiation (which travels only a few millimeters in tissue and does not easily penetrate the body), the external exposure to people nearby is extremely low. A study measuring radiation exposure from Y90 patients concluded that the effective dose to other individuals is very low when the administered dose is under 3 GBq, which covers the vast majority of treatments.²³ Most patients go home the same day or the day after the procedure without special radiation isolation precautions, though treatment centers may provide brief common-sense guidance about close contact with pregnant women or small children in the first few days.

Combining Y90 With Immunotherapy

One of the most active areas of research in liver cancer treatment is pairing Y90 with immune checkpoint inhibitors. The reasoning is straightforward: Y90 is effective at controlling tumors locally but cannot address disease that escapes the treatment field, while immunotherapy can produce systemic responses but works in only a minority of patients when used alone. Radiation may enhance the immune system’s ability to recognize and attack cancer cells by releasing tumor-specific antigens when it destroys tissue, essentially turning the treated tumor into a sort of vaccine. Combining the two could theoretically let each treatment compensate for the other’s weakness.²⁴ Early clinical trial data on the combination have been encouraging enough to fuel a growing number of trials, though the optimal sequencing, timing, and patient selection for this strategy remain open questions.

Cost and Accessibility

Y90 is an expensive procedure. The microspheres themselves carry a high price tag, and the multi-step treatment process (mapping angiogram, MAA scan, treatment session, follow-up imaging) adds up. Whether it represents good value depends heavily on the alternative. A cost-effectiveness analysis comparing Y90 resin microspheres to sorafenib (a systemic drug used for advanced HCC) in Brazil found that Y90 was cost-effective in that setting.²⁵ Cost calculations will differ by country, healthcare system, and the specific comparison being made. In the United States, most major insurance plans and Medicare cover Y90 for approved indications, though prior authorization is typically required. Access is concentrated at larger academic medical centers and specialized interventional radiology practices, so patients in rural areas may face practical barriers.

One factor that works in Y90’s favor economically is that it is usually done in a single treatment session (or two sessions if both lobes need treatment), and hospital stays are short, often just one night or even same-day discharge. Compared to repeated cycles of systemic therapy or multiple sessions of chemoembolization, the overall treatment burden on the patient’s schedule and the healthcare system can be lighter.